Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Randomized, Single-Centre, 3-Way Crossover Bioequivalence Study Comparing a Fixed Dose Combination Capsule of Esomeprazole 40 mg and Acetylsalicylic Acid 325 mg With Free Combinations of Esomeprazole Capsule 40 mg and Acetylsalicylic Acid Tablet 325 mg and Esomeprazole Tablet.

Next Previous
Trial Profile

A Phase I, Open-Label, Randomized, Single-Centre, 3-Way Crossover Bioequivalence Study Comparing a Fixed Dose Combination Capsule of Esomeprazole 40 mg and Acetylsalicylic Acid 325 mg With Free Combinations of Esomeprazole Capsule 40 mg and Acetylsalicylic Acid Tablet 325 mg and Esomeprazole Tablet.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin/esomeprazole (Primary) ; Aspirin; Esomeprazole
  • Indications Cardiovascular disorders; Embolism and thrombosis; Fever; NSAID-induced gastrointestinal damage; Pain; Rheumatic disorders; Stroke
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

Most Recent Events

  • 06 Dec 2010 Actual initiation date changed from Oct 2009 to Sep 2009 as reported by ClinicalTrials.gov.
  • 30 Jun 2010 Actual end date changed from Oct 2009 to Dec 2009 as reported by ClinicalTrials.gov
  • 30 Jun 2010 Actual patient number (138) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top